Phyla
San Francisco
About Phyla
Phyla is developing alternative therapies for antibiotics. The focus of most microbiome efforts is to discover beneficial bacteria to add to the microbiome, in order to cure disease or maintain health. However others lack a subtractive function that can remove harmful or disease-causing bacteria, that would allow the microbiome to rebalance and achieve a stable healthy state. Using bacteriophages as a foundation, they are developing a powerful platform that allows us to selectively 'subtract' bad bacteria without harming the good strains present in the community. It's a bit like using a sniper instead of a grenade to take out a bad guy in a crowd of people.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $3.2M
- Funding stage: Early Stage Venture
- Last round: Series A (Dec 2023)
- Website: phylabiotics.com
- Phone: 707-243-8820
Industries & Categories
Biotechnology, Health Care, Wellness
Social Profiles
Canonical: https://fsome.com/organization/phyla-10269 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.